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Abstract
Cyclin Dependent Kinase-2 Associated Protein-1 (CDK2AP1) is known to be a tumor sup-
pressor that plays a role in cell cycle regulation by sequestering monomeric CDK2, and tar-
geting it for proteolysis. A reduction of CDK2AP1 expression is considered to be a negative
prognostic indicator in patients with oral squamous cell carcinoma and also associated with
increased invasion in human gastric cancer tissue. CDK2AP1 overexpression was shown
to inhibit growth, reduce invasion and increase apoptosis in prostate cancer cell lines. In
this study, we investigated the effect of CDK2AP1 downregulation in primary human dermal
fibroblasts. Using a short-hairpin RNA to reduce its expression, we found that knockdown of
CDK2AP1in primary human fibroblasts resulted in reduced proliferation and in the induction
of senescence associated beta-galactosidase activity. CDK2AP1 knockdown also resulted
in a significant reduction in the percentage of cells in the S phase and an accumulation of
cells in the G1 phase of the cell cycle. Immunocytochemical analysis also revealed that the
CDK2AP1 knockdown significantly increased the percentage of cells that exhibited γ-H2AX
foci, which could indicate presence of DNA damage. CDK2AP1 knockdown also resulted in
increased mRNA levels of p53, p21, BAX and PUMA and p53 protein levels. In primary
human fibroblasts in which p53 and CDK2AP1 were simultaneously downregulated, there
was: (a) no increase in senescence associated beta-galactosidase activity, (b) decrease in
the number of cells in the G1-phase and increase in number of cells in the S-phase of the
cell cycle, and (c) decrease in the mRNA levels of p21, BAX and PUMA when compared
with CDK2AP1 knockdown only fibroblasts. Taken together, this suggests that the observed
phenotype is p53 dependent. We also observed a prominent increase in the levels of ARF
protein in the CDK2AP1 knockdown cells, which suggests a possible role of ARF in p53 sta-
bilization following CDK2AP1 knockdown. Altogether, our results show that knockdown of
PLOS ONE | DOI:10.1371/journal.pone.0120782 March 18, 2015 1 / 14
OPEN ACCESS
Citation: Alsayegh KN, Gadepalli VS, Iyer S, Rao
RR (2015) Knockdown of CDK2AP1 in Primary
Human Fibroblasts Induces p53 Dependent
Senescence. PLoS ONE 10(3): e0120782.
doi:10.1371/journal.pone.0120782
Academic Editor: Kenneth B Marcu, Stony Brook
University, UNITED STATES
Received: September 12, 2014
Accepted: February 6, 2015
Published: March 18, 2015
Copyright: © 2015 Alsayegh et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: Supported in part by NSF-CAREER
074556 (R. Rao) and NIH CTSA UL1TR000058
(R. Rao and S. Iyer) by VCU’s Center for Clinical and
Translational Research. The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
CDK2AP1 in primary human fibroblasts reduced proliferation and induced premature se-
nescence, with the observed phenotype being p53 dependent.
Introduction
CDK2AP1 is a cell cycle regulator that controls the G1-S phase transition by negatively regulat-
ing CDK2 [1]. In vitro studies focused on overexpression of CDK2AP1 in prostate cancer cell
lines results in a decrease in levels of CDK2 and its kinase activity, leading to an accumulation
of cells in the G1 phase and a reduction in cells that are in the S phase of the cell cycle [2]. This
outcome has been reasoned to be mediated by either the sequestration of monomeric CDK2 or
by targeting it for proteolysis. Another mechanism by which CDK2AP1 regulates G1-S phase
transition, is by directly binding the DNA polymerase/alpha-primase complex and inhibiting
the initiation step of DNA replication [3]. This inhibition may also be a result of CDK2AP1-
mediated reduction in CDK2 activity, which is known to stimulate DNA replication by phos-
phorylating the DNA polymerase-alpha-primase complex.
CDK2AP1 has also been found to mediate the growth inhibitory effects of TGF-β with stud-
ies in normal human keratinocytes treated with TGF-β, increased cellular levels of CDK2AP1
mRNA and protein [4]. Analysis of the results suggests that SMAD induced by TGF-β1 binds
at the proximal promoter of the CDK2AP1 gene. A significant correlative expression of TGF-β
receptor II (TGFβRII) and CDK2AP1 has been found in human oral squamous cell carcinoma
(OSCC) tissues with an observed loss of expression of CDK2AP1 and p21 [5]. It has also been
found that OSCC lines that were resistant to TGF-β, were unable to induce SMADs and
CDK2AP1, indicating a critical role for CDK2AP1 in mediating the growth inhibitory effects
of TGF-β [5]. The effects of overexpressing CDK2AP1 in prostate cancer cell lines, in which it
is downregulated were also evaluated [2]. Overexpression of CDK2AP1 in prostate cancer cell
lines lead to increased apoptosis, growth arrest and reduced invasion. In gastric cancer, it was
found that patients who had higher levels of CDK2AP1 in their samples had a better prognosis
than patients who had low levels of CDK2AP1 [6]. Although the previously mentioned studies
demonstrated the anti-tumorigenic role of CDK2AP1, a recent study revealed that knockdown
of CDK2AP1 in human glioma inhibited growth and tumorigenesis [7]. It was shown that
RNAi-mediated knockdown of CDK2AP1 in U251 and U373 human glioma cells resulted in
reduction in cell proliferation and arrested cells in G0/G1 phase of the cell cycle. Furthermore,
when xenograft formation was used to examine in vivo tumorigenesis, CKD2AP1downregula-
tion was found to inhibit tumor growth [7].
In this study, we aimed to investigate the effect of CDK2AP1 knockdown in normal primary
human dermal fibroblasts and demonstrate that knockdown of CDK2AP1 in these cells re-
sulted in reduced proliferation and p53-dependent senescence.
Materials and Methods
Generation of primary human fibroblasts expressing CDK2AP1-specific
shRNA and p53-specific shRNA
Primary human dermal fibroblasts (HDF) (Coriell Cell Repositories, NJ) were routinely main-
tained in medium containing MEM, 15% FBS, 100 U/ml penicillin and 100 μg/ml streptomy-
cin, with subculturing ratios of 1:4 using 0.05% Trypsin solution. All reagents were obtained
from Invitrogen (Carlsbad, CA) unless otherwise noted.
CDK2AP1 and Senescence
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We have identified two potent shRNAs targeted to CDK2AP1 mRNA. Multiple shRNAs
were obtained from commercially available sources (Open Biosystems, PA; Sigma-Aldrich,
MO) and screened for their effectiveness. Control scrambled sequences were used similarly. To
identify the shRNA clone that produced the strongest knockdown of CDK2AP1, human fibro-
blasts were transduced with the different shRNA clones using lentiviral vectors, and successful-
ly transduced cells were selected by puromycin treatment (3 μg/ml). Following 6 days of
selection, antibiotic-resistant cells were harvested and RNA extracted. QPCR analyses of
human CDK2AP1specific primers were conducted. In our experiments, one shRNA (labeled as
shRNA1 henceforth) (Open Biosystems, PA) produced the strongest knockdown and was used
in subsequent experiments. A second validated CDK2AP1 shRNA (labeled as shRNA2 hence-
forth) (Sigma-Aldrich, MO) that target the 3’-UTR, was also used in our studies. In experi-
ments involving analysis of the role of p53, expression was downregulated using lentiviral
delivery of p53-specific shRNA (Addgene, MA, USA), followed by validation of knockdown by
qPCR analyses.
RNA isolation, Real Time Reverse Transcription Polymerase Chain
Reaction (RT-PCR), and gene expression analysis
RNA isolation and gene expression analysis was performed as described previously [8]. Briefly,
RNA was isolated using RNeasy kit (Qiagen, CA, USA), according to the manufacturer’s proto-
cols and quantified using BioMate3 UV-VIS Spectrophotometer (Thermo Scientific, MA,
USA). Complimentary DNA (cDNA) was synthesized from 1 μg of RNA using cDNA reverse
transcription kit (Applied Biosystems, CA). Gene expression within different samples was ana-
lyzed using quantitative real time RT-PCR (QPCR). QPCR was performed in an ABI HT7900
system (Applied Biosystems, CA) and the data were acquired using sequence detection system
software (SDS v2.2.1, Applied Biosystems, CA). Gene expression data (three replicates) were
acquired and SDS software was used to estimate differential gene expression using ΔCT quanti-
fication methods. Endogenous GAPDH was used for normalization. Commercially available
primers for CDK2AP1 were obtained from Origene, MD, while other primers summarized in
S1 Table were obtained from Integrated DNA Technologies, IA.
Antibodies and Immunocytochemical analysis
Immunocytochemistry was performed as described previously [8,9]. In summary, human fi-
broblasts were seeded onto four chambered glass slides. Paraformaldehyde (PFA, 4%) in PBS
was used for fixation, permeabilization for intracellular markers was achieved with 0.2% Triton
X-100 in PBS and blocked with normal goat serum at room temperature. Fixed cells were incu-
bated with primary antibodies: CDK2AP1 (Santa Cruz, CA), Anti-phospho-Histone H2AX
(Millipore, CA). Goat anti-mouse IgG conjugated to Alexa 488 (for γ-H2AX staining) and
Goat anti-rabbit IgG conjugated to Alexa 594 (for CDK2AP1 staining) (Invitrogen, CA,) were
used as secondary antibodies. The samples were prepared for imaging by overnight exposure to
secondary antibody at 4°C followed by PBS washes, nuclear stain using DAPI (4’,6-diamidino-
2-phenylindole) and finally mounting the slides. Fluorescent images were acquired using a
CoolSnap EZ camera (Photometrics, Tucson, AZ) mounted on a Nikon Eclipse TE 2000-S in-
verted microscope (Nikon, Melville, NY) with attached image analysis software. All image set-
tings were controlled for uniform acquisition between samples. Specifically, a uniform
exposure time was maintained for images acquired from experimental samples as well as nega-
tive controls for background subtraction. Percentages of γ-H2AX positive cells were calculated
in multiple fields per sample (n = 28) by counting the number of cells containing at least 3 foci
in their nucleus and dividing by the total number of cells in each field of interest.
CDK2AP1 and Senescence
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Bromodeoxyuridine (BrdU) proliferation assay
For proliferation assays, fibroblasts under different experimental conditions in four-chambered
glass slides were propagated overnight, with subsequent incubation in medium containing 20
μg/ml Bromodeoxyuridine (BrdU) for a period of 2 hrs. Cells were then washed with ice cold
PBS buffer and fixed with 100% methanol at -20°C for 15 min. After fixation, cells were washed
in cold PBS and permeabilization achieved with 0.2% Triton X-100 in PBS. For DNA denatur-
ation (antigen retrieval), cells were treated with 2N HCl solution for 45 min at room tempera-
ture. To neutralize the HCl solution, Borate buffer was added for 6 min and cells washed.
Blocking was achieved by treatment with 3% goat serum in medium for 45 min at room tem-
perature. Fixed cells were incubated with Anti-BrdU (Abcam, MA) as the primary antibody.
Goat anti-rat IgG conjugated to Alexa 594 (Invitrogen, CA) was used as a secondary antibody.
The samples were prepared for imaging by overnight exposure to secondary antibody at 4°C
followed by PBS washes, nuclear stain using DAPI (4’,6-diamidino-2-phenylindole) and finally
mounting the slides. To determine the percentage of BrdU positive cells, slides were viewed at
20X magnification and random fields chosen in which total number of cells was determined by
counting DAPI, followed by counting the BrdU-positive cells. Triplicate counts of at least 500
cells each were acquired and the percentage of BrdU positive cells was determined by dividing
the number of BrdU positive cells by total number of cells.
Cell cycle profile analysis
Cell cycle analysis was performed as described previously [10]. Cells to be analyzed were trypsi-
nized, washed, stained with propidium iodide for 45 min at 37°C, filtered through a 30 μm
mesh to eliminate clumps and subjected to cell cycle analysis on an Accuri C6 Flow Cytometer
(BD Biosciences, CA). Data were analyzed using the software provided by the manufacturer
and samples analyzed in triplicate.
Senescence associated β-galactosidase assay
Cells to be assayed were seeded in 6-well plates for the senescence-associated b-galactosidase
assay. After 24 h, cells were fixed and stained with X-gal for detection of b-galactosidase activity
using a senescence b-galactosidase staining kit (Cell Signaling, MA). After 24 h incubation,
cells exhibiting positive β-galactosidase activity (turned blue) at pH 6.0 were counted under a
light microscope. The percentage of cells exhibiting positive staining was determined in 10 in-
dividual fields of interest.
Western Blotting
Western Blotting was performed as described previously [9]. Cells for analysis were harvested
by trypsinization, centrifuged at 1000 rpm and washed once with ice-cold PBS buffer. Cells
were then lysed using the Total Protein Extraction Kit (EMDMillipore, MA) based on protocol
provided by the manufacturer. Cell lysates were then subjected to Western blot analyses using
specific antibodies to various cyclins. Cell lysates were prepared from wild type and CDK2AP1
knockdown primary human fibroblasts and analyzed for p53, p21 and β-tubulin expression by
Western blot using specific antibodies. p53 and p21 antibodies were obtained from Cell Signal-
ing, MA, p14ARF antibodies were obtained from Santa Cruz Technologies, while β-tubulin anti-
body was obtained from Developmental Studies Hybridoma Bank, IA. Appropriate infrared
emitting-conjugated secondary antibodies were obtained from Invitrogen, CA. Detection was
then carried out using the Odyssey Infrared Imaging System (Li-Cor Biosciences, NE).
CDK2AP1 and Senescence
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Results
Knockdown of CDK2AP1 in primary human fibroblasts results in
decreased cell proliferation and alters cell cycle profile
To investigate the effect of CDK2AP1 knockdown on the growth of primary human fibroblasts,
we used lentiviral delivery of shRNA1 to downregulate CDK2AP1 in primary human dermal fi-
broblasts. CDK2AP1 expression was then examined using qPCR (Fig. 1A) and immunocyto-
chemistry (Fig. 1B). Based on qPCR analysis, we were able to achieve 90% knockdown of
CDK2AP1, with statistical analysis indicating significant differences (p<0.05) in the expression
patterns between primary human fibroblasts transduced with the shRNA1 and normal fibro-
blasts. Additional line was created by transducing with a second different CDK2AP1 shRNA
(shRNA2) which resulted in a 96% knockdown of CDK2AP1 (Fig. 1A). Following the genera-
tion of CDK2AP1 knockdown primary human fibroblasts, we examined the effect of the knock-
down on cell proliferation. Initial analyses conducted in triplicate using hemocytometer to
count cells, indicated that CDK2AP1 knockdown cells exhibited an extremely slow rate of pro-
liferation, suggesting that depletion of CDK2AP1inhibited cell proliferation (Fig. 1C). Subse-
quent analysis using the BrdU proliferation assay indicated that the CDK2AP1 knockdown cells
had a significantly lower BrdU incorporation than the wild type fibroblasts (p-value = 0.002)
(S1 Fig.). Taken together, these results suggest that the knockdown of CDK2AP1 in primary
human fibroblasts decreases proliferation.
Cell cycle analysis was then conducted on an equal number of HDFs transduced with an
empty vector (EV) or HDFs transduced with CDK2AP1 shRNA1 or HDFs transduced with
CDK2AP1 shRNA2. Analysis demonstrated that the knockdown of CDK2AP1 significantly in-
creased cells in the G1 phase of the cell cycle from 78% in the control cells to 94% in CDK2AP1
shRNA1 transduced cells (p-value = 0.00026) to 95% in CDK2AP1 shRNA2 transduced cells
(p-value = 0.00022) (Fig. 1D). In addition, knockdown resulted in a significant decrease in the
percentage of cells in the S-phase of the cell cycle from 8% in the control cells to 1.3% in the
CDK2AP1-shRNA1 transduced cells (p-value = 0.005) and to 0.6% in the cells transduced
CDK2AP1-shRNA2 (p-value = 0.004) (Fig. 1D). Under each condition, we also observed few
necrotic/apoptotic cells present in the sub G0/G1 phase of the cell cycle with 7% in the control
sample, and 3% and 4% in the CDK2AP1-shRNA1 and CDK2AP1-shRNA2 transduced cells,
respectively. Taken together, these results indicate that the depletion of CDK2AP1 prevents
progression from the G1 to the S phase of the cell cycle.
Knockdown of CDK2AP1 in primary human fibroblasts induces
premature senescence
During the period of monitoring cell viability, we observed that CDK2AP1 knockdown fibro-
blasts displayed a flattened cellular morphology with progressive cell passage number. To in-
vestigate whether CDK2AP1 knockdown leads to growth arrest, HDFs transduced with an
empty vector or HDFs transduced with CDK2AP1-shRNA1 or HDFs transduced with
CDK2AP1-shRNA2, were plated for senescence associated β-galactosidase assay (SA-β-gal),
typically after 12 days post-transduction. Detection of β-galactosidase activity at pH 6.0 is a
known characteristic of senescent cells [11]. We found that 91.7% of HDFs transduced with
CDK2AP1-shRNA1 and 70.8% of CDK2AP1-shRNA2 transduced cells displayed appearance
of enlarged blue cells in contrast to the control EV transduced cells, which failed to exhibit a de-
tectable blue appearance (Fig. 2). Therefore, these results suggest that knockdown of
CDK2AP1 leads primary human fibroblasts to undergo premature senescence.
CDK2AP1 and Senescence
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Knockdown of CDK2AP1 in primary fibroblasts increases DNA damage
To ascertain the reason behind the unexpected reduced proliferation of the CDK2AP1 knock-
down HDFs, we hypothesized that CDK2AP1 knockdown might contribute to a temporary ab-
normal increase in the progression into S-phase of the cell cycle and hence, an uncontrolled
increase in DNA synthesis. This is based on the reported function of CDK2AP1 as a negative
regulator of CDK2 and we expected that this could be contributing to errors in DNA synthesis
and DNA damage [3].
To examine this possibility, we measured the number of γ-H2AX foci in equal numbers of
CDK2AP1-shRNA1, CDK2AP1-shRNA2 or EV transduced cells that were seeded onto
4-chamber slides and stained using γ-H2AX antibody. We found that the knockdown of
CDK2AP1 in HDFs resulted in a significant increase in γ-H2AX foci with 70% of the CDK2AP1-
shRNA1 HDFs and 84.5% CDK2AP1-shRNA2 cells staining positive, while only 25% of EV cells
were positive, indicating a potential increase in DNA damage upon CDK2AP1 knockdown
(Fig. 3). Additionally, nuclear staining with DAPI dye indicated that the CDK2AP1-knockdown
cells exhibited a high number of micronuclei that were surrounding the nuclei of the cells; a phe-
nomenon not observed in the control fibroblasts (S1 Fig.). This observation might be considered
Fig 1. Knockdown of CDK2AP1 in HDFs reduces proliferation and induces G1 phase arrest. Panel A: Primary HDFs were transduced with an empty
vector or with CDK2AP1 specific shRNA1 or 2. Following antibiotic selection, cells were examined for CDK2AP1 expression using qPCR. CDK2AP1 was
successfully downregulated using both shRNA’s when compared to EV transduced cells. Panel B: HDFs were transduced with CDK2AP1 shRNA1 or a
scrambled-sequence shRNA and stained with a CDK2AP1 specific antibody. Panel C: CDK2AP1 knockdown inhibited proliferation of HDFs. Cells were
plated after selection, and counted at different time points by trypan blue exclusion method. Panel D: Asynchronized wild type and CDK2AP1 knockdown
HDFs were harvested and stained with propidium iodide. DNA content was analyzed by flow cytometry. Results are presented together with standard
deviation from experiments conducted in triplicate.
doi:10.1371/journal.pone.0120782.g001
CDK2AP1 and Senescence
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evidence of genomic instability that the knockdown fibroblasts might have experienced before
they entered senescence.
Knockdown of CDK2AP1 increases the levels of p53 and its target
genes, p21, BAX and PUMA
Following CDK2AP1 knockdown in primary HDFs we observed a decrease in cell prolifera-
tion, a G1 phase arrest and an increase in cellular senescence. These findings may indicate an
increase in the levels of the tumor suppressor p53. Indeed we have found that HDFs in which
CDK2AP1 was down regulated had a significant increase in p53 protein levels (Fig. 4). Given
Fig 2. Knockdown of CDK2AP1 altered the morphology of HDFs and increased senescence-associated β-galactosidase activity.HDFs that were
transduced with an empty vector (EV) or CDK2AP1-shRNA1 or CDK2AP1-shRNA2, were seeded and grown in a 6-well plate and senescence-associated β-
galactosidase assay was performed. CDK2AP1 knockdown fibroblasts displayed a significantly higher senescence associated β-galactosidase activity. The
percentage of cells exhibiting β-galactosidase activity is shown at the top of each panel in the right.
doi:10.1371/journal.pone.0120782.g002
CDK2AP1 and Senescence
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that the p21 is a downstream transcriptional target of p53 and plays a role in cell cycle arrest
and senescence, we measured its mRNA and protein levels in CDK2AP1 wild type and knock-
down HDFs [12]. We found that p21mRNA levels increased by 2.1 fold in the CDK2AP1-
shRNA1 cells and by 1.8 fold in the CDK2AP1-shRNA2 HDFs when compared with EV
transduced cells (Fig. 4A). Western blot analysis further confirmed the increase in p21 protein
levels (Fig. 4B).
Due to observed decrease in cell viability upon CDK2AP1 knockdown, we also decided to
examine the expression of candidate p53-responsive apoptotic genes, BAX and PUMA. QPCR
analysis indicated that BAXmRNA levels were increased by 1.5 fold in the CDK2AP1-shRNA1
transduced HDFs and by 2.4 fold in the CDK2AP1-shRNA2 when compared with EV
Fig 3. Knockdown of CDK2AP1 in Primary HDFs Increases γ-H2AX Signal. Panel A: Primary HDFs were either transduced with empty vector (EV),
CDK2AP1-shRNA1 or CDK2AP1-shRNA2. Following antibiotic selection, immunocytochemistry was carried out using a γ-H2AX specific antibody.
Percentage of γ-H2AX was calculated in multiple (n = 28) randomly selected fields by dividing the number of γ-H2AX positive cells by total number of cells in
the field. Results are presented together with standard deviation frommultiple fields of view (*-p-value< 0.05). Panel B: Example of EV and CDK2AP1-
shRNA1 cells stained with γ-H2AX (green) and the nuclear dye, DAPI (blue). Scale bar represents 50 μm.
doi:10.1371/journal.pone.0120782.g003
CDK2AP1 and Senescence
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transduced cells. Similarly, we observed that PUMAmRNA levels were increased by 2.0 fold in
the CDK2AP1-shRNA1 cells and by 3.6 fold in cells transduced with CDK2AP1-shRNA2
when compared with EV cells.
It is also worth noting that we have observed an increase in p53mRNA levels (Fig. 4A) in
CDK2AP1 knockdown cells (2.3 fold and 1.89 fold increase in CDK2AP1-shRNA1 HDFs and
CDK2AP1-shRNA2 respectively). CDK2AP1 is known to be a member of the Nucleosome Re-
modeling and Deacetylation (NuRD) Complex [13], which is a repressive complex responsible
for epigenetic regulation of numerous genes. Downregulation of members of the NuRD com-
plex has been previously associated with the transcriptional activation of p53 [14]. Therefore,
we speculate that the knockdown of CDK2AP1 may have led to aberrant epigenetic regulation
of the p53 gene, leading to abnormal increase in its transcription.
Knockdown of CDK2AP1 Increases p14ARF Protein Levels
P14ARF is an alternative reading frame protein product of the CDKN2A locus which functions
as a cell cycle regulator [15], and is activated by oncogenic signals, like excessive inactivation of
the retinoblastoma protein (pRB) and increased E2F1 activity [16]. P14ARF is directly activated
by the E2F1 transcription factor and directly binds the p53 negative regulator, HDM2 and se-
questers it in the nucleolus [15]. By antagonizing HDM2, p14ARF allows p53 transcriptional ac-
tivity which would lead to decreased cell proliferation and apoptosis.
We thus speculated that knockdown of CDK2AP1 might have caused an oncogenic insult
as a result of increased CDK2 activity. This may aberrantly increase E2F1 which would increase
the levels of p14ARF. Using whole cell lysates from CDK2AP1 wild type and knockdown HDFs,
we conducted Western Analysis and observed a significant increase in the protein levels of
p14ARF as expected (Fig. 4C). This suggests that the increase in p14ARF maybe the underlying
cause of p53 upregulation and the observed phenotype in the CDK2AP1 HDFs.
Observed Senescence in CDK2AP1 Knockdown Primary HDFs is p53
Dependent
Following CDK2AP1 knockdown, we have observed an increase in p53 levels (Fig. 4). The in-
crease in p53 may have resulted in the observed increase of the transcription of p21, BAX and
PUMA (Fig. 4A). To investigate if the observed increase in the levels of transcription of the
aforementioned genes in the CDK2AP1 knockdown primary HDFs is p53 dependent, we co-
transduced primary HDFs with p53 and CDK2AP1 shRNAs and assayed CDK2AP1, p53, p21,
Fig 4. Knockdown of CDK2AP1 increases the expression of p53, p21 and the Apoptotic Genes BAX and PUMA. Panel A: HDFs transduced with EV,
CDK2AP1-shRNA1 or CDK2AP1-shRNA2 were harvested and analyzed for the mRNA expression of p53, p21, BAX and PUMA. Knockdown of CDK2AP1 in
HDFs increased the expression of these genes. Panel B: Whole cell lysates were extracted from wild and knockdown HDFs and analyzed for p21 and p53
levels by Western Blot. Panel C: Whole cell lysates were extracted from wild and knockdown HDFs and analyzed for p14ARF byWestern Blot.
doi:10.1371/journal.pone.0120782.g004
CDK2AP1 and Senescence
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BAX and PUMA expression by qPCR analysis. The double-knockdown cells exhibited signifi-
cantly lowered expression of p53, p21, BAX and PUMA (p-value<0.05) when compared with
CDK2AP1 only knockdown cells (Fig. 5A), thus suggesting that the observed increase in p21,
BAX and PUMA transcription levels in the CDK2AP1 only knockdown cells is p53 dependent.
In experiments conducted with primary HDFs, we found that knockdown of CDK2AP1 re-
sulted in increased percentage of cells in the G1 phase of the cell cycle and prevented progres-
sion from the G1 to the S phase of the cell cycle (Fig. 1D). To test dependence on p53
expression, we examined the cell cycle profile of primary HDFs that were co-transduced with
p53 and CDK2AP1 shRNAs. We found that the knockdown of p53 significantly increased the
percentage of cells in the S phase (p-value = 0.0007) and reduced the cells in G1 phase of the
cell cycle (p-value = 0.0004) (Fig. 5B) when compared to CDK2AP1 knockdown only primary
HDFs (Fig. 1D).
To investigate if the simultaneous knockdown of p53 and CDK2AP1 in primary HDFs
would prevent premature senescence, HDFs transduced with an empty vector or HDFs trans-
duced with CDK2AP1 shRNA1 or HDFs transduced with CDK2AP1 shRNA2 and exogenous
Fig 5. Observed phenotype following CDK2AP1 knockdown is p53 dependent. Panel A: Primary HDFs were transduced with EV or CDK2AP1-shRNA
or CDK2AP1-shRNA and a p53 specific shRNA and were analyzed by qPCR for mRNA levels of p53, p21, BAX and PUMA. Knockdown of p53 with
CDK2AP1 prevented the increase in p21, BAX and PUMA. Panel B: The knockdown of p53 with CDK2AP1 increased the percentage of cells in the S and
reduced the cells in G1 when compared to CDK2AP1 only knockdown cells (p-value< 0.05). Results are presented together with standard deviation from
experiments conducted in triplicate. Panel C: HDFs that were transduced with an EV, CDK2AP1 shRNA1, CDK2AP1 shRNA2 and exogenous CDK2AP1
(CDK2AP1-shRNA2+CDK2AP1) or CDK2AP1 shRNA2 and p53 shRNA (CDK2AP1-shRNA2+shp53) were seeded onto a 6-well plate and senescence-
associated β-galactosidase assay was performed. Simultaneous knockdown of CDK2AP1 and p53 results in significantly reduced senescence associated β-
galactosidase activity. The percentage of cells exhibiting β-galactosidase activity is shown at the top of each panel.
doi:10.1371/journal.pone.0120782.g005
CDK2AP1 and Senescence
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CDK2AP1 (CDK2AP1-shRNA2 + CDK2AP1) or HDFs transduced with CDK2AP1 shRNA2
and p53 shRNA (CDK2AP1-shRNA2 + shp53) were plated for senescence associated
β-galactosidase assay (SA-β-gal). Cells were fixed and stained with X-gal for the detection
of β-galactosidase activity (Fig. 5C). Our results indicate that the fibroblasts that were co-
transduced with the CDK2AP1 and p53 shRNAs did not enter premature senescence and had
extremely low β-galactosidase activity. Taken together, these results indicate that downregula-
tion of CDK2AP1 increases p53 expression which pushes primary human fibroblasts to enter a
p53 dependent premature senescence.
Discussion
The function of CDK2AP1 as initially assessed in multiple cancer cell lines indicates its role in
regulation of apoptosis, proliferation and invasion [2]. Although the primary function of
CDK2AP1 as a cell cycle regulator that controls the G1-S phase transition by negatively regu-
lating CDK2 has been ascertained [1], its role in primary human fibroblasts has not been stud-
ied. To investigate the function of CDK2AP1 in primary human fibroblasts, we knocked down
CDK2AP1 expression in primary human dermal fibroblasts (HDFs) using short hairpin RNA.
Using a lentiviral approach, we were able to downregulate CDK2AP1 by ~90%. Following
knockdown of CDK2AP1 in primary HDFs, we observed a distinct reduction in the prolifera-
tion potential of these cells, with the cells exhibiting morphological changes as well. The
CDK2AP1 knockdown HDFs appeared enlarged, flat and more spread out. Given that reduced
proliferation and flattened morphologies is a sign of premature senescence in primary somatic
cells, we decided to examine the CDK2AP1 knockdown HDFs for senescence associated
β-galactosidase activity. Results indicated that CDK2AP1 knockdown HDFs displayed a signif-
icantly higher senescence associated β-galactosidase activity.
Given that CDK2AP1 is a known inhibitor of CDK2 and has also been reported to associate
with the DNA polymerase/alpha primase complex [1,3], we expected that following its knock-
down, the inhibition might have been alleviated allowing abnormal increase in DNA synthesis,
which could lead to DNA damage. Using immunocytochemical analysis, we examined the
CDK2AP1 knockdown cells for levels of γ-H2AX foci, a known indicator of DNA damage. Our
results indicated that the CDK2AP1 knockdown HDFs had significantly higher number of
cells that were γ-H2AX positive (having more than three γ-H2AX foci in each cell). Additional-
ly, we observed that the CDK2AP1 knockdown HDFs had a high number of micronuclei that
were surrounding the nuclei when examined by DAPI staining (S2 Fig.). These findings might
be considered evidence of genomic instability that the CDK2AP1 knockdown HDFs might
have experienced before they entered senescence.
Also, following CDK2AP1 knockdown, an increase in CDK2 activity may have occurred,
causing an abnormal increase in the phosphorylation of the pRB protein and a deregulation in
the G1-S phase transition. A previous study demonstrated that Cdk2ap1 deletion indeed re-
sulted in hyperphosphorylation of pRB [18]. Hyperphosphrylation of the pRB protein would
increase the activity of the transcription factor E2F1 which in turn, would bind the promoter of
p14ARF and induce an increase in its levels. We have found that CDK2AP1 knockdown in pri-
mary HDFs resulted in a prominent increase in the levels of p14ARF protein. As mentioned ear-
lier, p14ARF antagonizes HDM2 and promotes an increase in p53 levels [16]. Therefore, we
expect that the observed phenotype is a result of p14ARF-mediated increase in p53 activity. The
role of p14ARF in response to DNA damage has also been demonstrated in a recent study, with
results indicating that that persistent DNA damage increases the levels of p14ARF and that the
increase is ATM dependent [19]. P14ARF then allows p53 transcription of the phosphatases
DUSP4 and DUSP7, which in turn dephosphorylates ERK1 and inhibit cell proliferation.
CDK2AP1 and Senescence
PLOS ONE | DOI:10.1371/journal.pone.0120782 March 18, 2015 11 / 14
Therefore, in future experiments, it would be useful to attempt to reverse the senescence ob-
served in CDK2AP1 knockdown primary human fibroblasts by downregulating p14ARF or
ATM, given that the DNA damage response (DDR) pathway via ATM activation and ARF are
stress responders and activate p53, while ATM also keeps in check ARF activation [20,21].
Although the majority of existing reports support the role of CDK2AP1 to be a tumor sup-
pressor, recent studies have shown that knockdown of CDK2AP1 in human glioma cells re-
duced proliferation, caused a G0/G1 cell cycle arrest and increased apoptosis [7]. Following
CDK2AP1 knockdown in primary human fibroblasts, we have also observed a reduction in
proliferation, a G0/G1 arrest and an increase in p21 and the candidate p53-responsive apopto-
tic genes BAX and PUMA when examined by qPCR (Fig. 4).
Given that CDK2AP1 acts as a regulator of G1 to S phase progression by inhibiting CDK2,
knockdown of CDK2AP1could aberrantly increase the activity of E2F1 through pRB inactiva-
tion. By being a downstream transcriptional target of E2F, p14ARF is activated by oncogenic sig-
nals, and through modulation of MDM2, promotes the increase in p53 levels [16,17]. To our
knowledge there are no studies that prove that the deletion of CDK2AP1 alone can transform
cells. Therefore we speculate that the ability of a deleterious mutation in CDK2AP1 to trans-
form cells is highly dependent on the presence of an additional mutation in other tumor sup-
pressor like p21, p27, p14ARF or p53. In the study conducted with human gastric cancer tissues
(n = 180), it was determined that p53 expression was negative in 95 (54%), while CDK2AP1 ex-
pression was negative in 140 (77%), with no apparent correlation found between CDK2AP1
and p53 expressions. However, it is important to note that the study only examined the levels
of CDK2AP1 and p53. Detection and analysis of other mutations in the context of negative ex-
pression of CDK2AP1 is worthy of further study.
Downregulation of CDK2AP1 in cancer cells could thus result in beneficial growth inhibito-
ry effects. This would only be possible if the tumor suppressors or the genes involved in the
pathway activated by CDK2AP1 knockdown which causes growth inhibition were normal and
not mutated in the cancer cell line of interest. Therefore, further studies are needed to identify
the pathway responsible for the observed anti-tumorigenic effects of CDK2AP1 knockdown, so
its potential can be examined in the appropriate cancer cell lines.
CDK2AP1 has also been reported to be a member of the epigenetically repressive complex,
NuRD [13]. A previous study demonstrated that disruption of a member of the NuRD complex
leads to an increase in p53 levels [14]. In our studies, we have observed an increase in p53 tran-
scription following CDK2AP1 knockdown, which could be a result of the disruption of the
NuRD complex. Deletion of CDK2AP1 has been previously reported to alter epigenetic marks
on genes that are regulated by the NuRD complex, and these genes could not be silenced in the
absence of CDK2AP1 due to disrupted localization of NuRD [22]. Therefore, it is possible that
following CDK2AP1 knockdown, the NuRD complex could not localize properly to regulate
p53 transcription, which could thus have caused the observed increased levels of p53 in the
CDK2AP1 knockdown HDFs.
Given the observed increase in p53 levels upon CDK2AP1 knockdown, we decided to exten-
sively examine the dependence on p53 in the CDK2AP1 knockdown HDFs. We observed that
when p53 and CDK2AP1 were simultaneously downregulated in primary HDFs, the cells did
not enter senescence based on reduced senescence associated β-galactosidase activity. The si-
multaneous knockdown of p53 and CDK2AP1 also led to reduction of accumulation of cells in
the G1 phase and increased cells in the S phase of the cell cycle. qPCR analysis further demon-
strated that knockdown of p53 in HDFs prevents the CDK2AP1 knockdown induced increase
in p21, BAX or PUMA gene expression. Together, these results lead us to conclude that the
CDK2AP1knockdown induced senescence in primary HDFs is p53 dependent.
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Supporting Information
S1 Fig. Knockdown of CDK2AP1 in primary HDFs reduces BrdU incorporation. A. Cells
transduced with an empty vector (EV) or CDK2AP1-shRNA1 were labeled with 20 μM BrdU
for 2 h, fixed and stained with a BrdU specific antibody and the percentage of BrdU positive
cells was calculated. Results are presented together with standard deviation from experiments
conducted in triplicate. (-p-value< 0.05). B. Showing representative pictures of the quantified
immunocytochemistry. BrdU positive cells are shown in red, nuclei were stained with DAPI
(blue). Scale bar represent 50 μm.
(TIF)
S2 Fig. Knockdown of CDK2AP1 in primary HDFs leads to increased micronuclei forma-
tion. Red arrows point to micronuclei, which may be a sign of genetic instability in these cells.
Scale bar represents 100 μm.
(TIF)
S1 Table. Sequences of primers used in qPCR analysis.
(DOC)
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